Spots Global Cancer Trial Database for Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma

Official Title: Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma

Study ID: NCT00803907

Conditions

Carcinoma, Basal Cell

Interventions

Imiquimod 5% cream

Study Description

Brief Summary: This study aimed to prove the efficacy and safety of the use of imiquimod 5% cream in the periorbital region.

Detailed Description: This is a prospective study including patients presenting in aggregate primary lesions affected by nodular BCC of the eyelid (all subjects were submitted to incisional biopsy at 2 mm punch) at the commencement of this study. All were submitted to a local treatment with Imiquimod 5% cream (Aldara ®), once daily, 5 days per week for 8-16 weeks (average). All subjects were submitted to a new incisional biopsy at 2 mm punch, after 12 weeks of treatment, and all of them were monitored monthly up to now.If positive biopsy (residue tumor) cases will managed with surgery.